Related references
Note: Only part of the references are listed.Dysregulation of bone remodeling by imatinib mesylate
Kate Vandyke et al.
BLOOD (2010)
Neoadjuvant Platelet Derived Growth Factor Receptor Inhibitor Therapy Combined With Docetaxel and Androgen Ablation for High Risk Localized Prostate Cancer
Paul Mathew et al.
JOURNAL OF UROLOGY (2009)
Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer
P. Mathew et al.
BRITISH JOURNAL OF CANCER (2008)
Tandutinib inhibits FMS receptor signalling, and macrophage and osteoclast formation in vitro
N. Brownlow et al.
LEUKEMIA (2008)
Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting
Kristian Pietras et al.
PLOS MEDICINE (2008)
Long-term imatinib therapy promotes bone formation in CML patients
Stephen Fitter et al.
BLOOD (2008)
Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms
Susannah O'Sullivan et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases
Paul Mathew et al.
CLINICAL CANCER RESEARCH (2007)
Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy
Gopal K. Bajaj et al.
UROLOGY (2007)
Imatinib mesylate (Gleevec®) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity
Iman El Hajj Dib et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2006)
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics
Daniel J. DeAngelo et al.
BLOOD (2006)
A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy
Amy M. Lin et al.
BJU INTERNATIONAL (2006)
Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer
Sun-Jin Kim et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer
K Rao et al.
PROSTATE (2005)
Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: A modular phase I trial in androgen-independent prostate cancer
P Mathew et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases
H Uehara et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family
A Pandey et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Share Paper
